AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1

By A. Didierlaurent, S. Morel, L. Lockman, S. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti and 3 more. Journal of Immunology, 2009

743 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology

View Paper: https://www.semanticscholar.org/paper/b6a80b5da360c286ef1fd84261174298f65e8282

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Kui Li
2. Sandra N. Lester

In Immunology

1. Kui Li
2. Sandra N. Lester

Citations in the corpus

• Mechanisms of Action of Adjuvants (2013, background): “…II and MHC class I to CD4+T cells and CD8+T cells respectively Immunopotentiator Ab, antibody; Ag, antigen; CTL, cytotoxic T lymphocytes; dLNs, draining lymph nodes. www.frontiersin.org May 2013 | Volume 4 | Article 114 | 3 vaccine, along with providing a depot effect (Didierlaurent et al., 2009).”
• Toll-like receptors in antiviral innate immunity (2013, background): “Currently, the TLR4 agonist monophosphoryl lipid A has been approved as an adjuvant component in a hepatitis B virus vaccine and a human papillomavirus vaccine [225,226].”
• Vaccine adjuvants: mechanisms and platforms (2023, methodology): “AS04 is currently approved primarily for use in human papillomavirus (HPV) vaccine (Cervarix) and HBV vaccines (Fendrix) to increase antibody production and activation of antigen-specific T cells.(165,174) CpG ODN 1018 is a synthetic single-stranded DNA molecule, which has been extensively studied a”
• Peptide Vaccine: Progress and Challenges (2014, methodology): “AS04 was also developed by GSK and used as the adjuvant for viral vaccines including hepatitis B (Fendrix ® ), and HPV (Cervarix ® ) [111].”